Navigation Links
Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Date:10/28/2008

to HIV infection.

"These data provide good support for the evaluation of our first ZFN-based ZFP Therapeutic in man," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "It was observed more than ten years ago that individuals carrying the natural CCR5-delta32 mutation were highly resistant to infection by HIV. Consequently, a variety of small molecule and antibody approaches have been tested as potential therapeutics. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. We believe that our ZFN technology provides an approach that circumvents the dosing and potential toxicity issues of a systemic therapy. By specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs, we can generate a population of R5-tropic HIV-resistant T-cells.

We have shown that these ZFN-modified human cells are made permanently resistant to infection by HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections characteristic of AIDS and HIV itself. The modified cells exhibited the expected properties of normal CD4 T-cells. These data also demonstrate that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic. We intend to file an investigational new drug (IND) application for this ZFP Therapeutic this year and begin a clinical trial as soon as possible."

Data Reported in the ICAAC/IDSA Presentation

The reported results demonstrate that a one-time exposure to CCR5-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
4. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
5. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
6. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
7. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
8. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
9. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
10. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... The shortlist of contenders for the highest ... narrowed tonight as the winners of the Siemens ... Finals were announced.  Cancer stem cell research earned ... Angela Zhang of Cupertino, California.  Research on molecular ...
... working at Argonne National Laboratory,s (ANL) Center for Nanoscale ... into nanowires, boosting the material,s functionality and providing potential ... led by Anirudha Sumant, a materials scientist at ANL, ... & Exhibition, held Oct. 30 Nov. 4, 2011, ...
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... that all six proxy resolutions passed at a special ... statement was filed with the Securities and Exchange Commission ... and on the Company,s web site:   www.radient-pharma.com ...
Cached Biology Technology:Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 3Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 4Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 5Scientists carve nanowires out of ultrananocrystalline diamond thin films 2Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders 2
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
(Date:12/10/2014)... Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) has announced the ... report to their offering. ... and smart cards for projects such as rural banking ... the major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... Tumor metastasis, the ability of cancer cells to migrate from ... accounts for over 90% of cancer deaths. When patients die ... by malignant cells that split off from the primary cancer ... the Ludwig Center at the University of Chicago hypothesized over ...
... School of Medicine and AstraZeneca, a global biopharmaceutical company, ... 2a trial to assess the effectiveness of AZD5847, a ... patients with HIV co-infection. The study is sponsored ... (NIAID), part of the U.S. National Institutes of Health. ...
... 2002-2003 was short-lived, but a novel type of human coronavirus ... humans and bats alike, a fact that could make the ... to be published in in mBio , the online ... 11. The new coronavirus, called hCoV-EMC, is blamed for five ...
Cached Biology News:Predictors of cancer disease progression improve patient selection for metastasis-directed therapy 2New tuberculosis drug trial begins in South Africa 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 3
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
Request Info...
Biology Products: